Chemical and Structural Approaches to Study Energy Homeostasis Pathways in Cancer and Metabolic disorders
研究癌症和代谢紊乱能量稳态途径的化学和结构方法
基本信息
- 批准号:10405224
- 负责人:
- 金额:$ 46.45万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2017
- 资助国家:美国
- 起止时间:2017-09-18 至 2027-07-31
- 项目状态:未结题
- 来源:
- 关键词:Alzheimer&aposs DiseaseAutophagocytosisBindingBiologyCellsChemicalsCollaborationsCommunitiesComplexCrystallizationCrystallographyDegradation PathwayDiabetes MellitusDiseaseDisease modelEnzymesFamilyFamily memberFundingGenerationsGenetic DiseasesGoalsHomeostasisHuman BiologyHuman PathologyInborn Errors of MetabolismInstitutesLinkLysineMalignant NeoplasmsMetabolicMetabolic DiseasesMetabolic PathwayMolecularNerve DegenerationO-GlcNAc transferasePathway interactionsPatientsPharmaceutical ChemistryPhosphotransferasesPositioning AttributeQuality ControlResearchResolutionRoleSchizophreniaStarvationStructureVisioncancer geneticsdiabetes mellitus geneticsdrug discoveryenzyme structureglutaric acidemiaglycosyltransferasehuman diseaseinhibitormultidisciplinarynanomolarprogramsprotein degradationproteostasissensorstructural biologytherapeutic target
项目摘要
Project Summary
The overall research in the Lazarus Lab revolves around studying energy and protein homeostasis as it
relates to human disease using chemical biology and structural biology. We have several multidisciplinary
projects around this topic, including studying the ULK family of autophagy kinases and pseudokinases, lysine
metabolism disorders, and other kinases related to diabetes and cancer. Over the last 4 years, we have used
crystallography and chemical biology to help develop highly potent inhibitors of the metabolic sensor O-GlcNAc
transferase, solved the first structures and identify the first chemical probes of the ULK pseudokinase linked to
schizophrenia ULK4, and helped elucidate the first structure of an enzyme in the lysine metabolic pathway
DHTKD1.
Our goals over the next five-year period include further understanding of the ULK family of kinases.
ULK1 and ULK2 are the main initiating enzymes for the autophagy pathway, a conserved metabolic pathway
whereby cellular components get degraded for quality control and energy generation during starvation. The
pathway is thought to be critical in diseases ranging from cancer to Alzheimer’s disease, yet there are still
major gaps in our understanding of the pathway. What happens to cells when you inhibit autophagy at different
stages of the pathway in different disease models using selective probes? What is the role of the mysterious
family member ULK4, which has no catalytic activity but binds ATP with nanomolar potency and likely has a
function for the ATP binding. Another major goal involves the lysine metabolic pathway, in which several inborn
errors of metabolism are found. How do the enzymes in this pathway function, and can inhibiting other
enzymes in this pathway block the toxic buildup of intermediates that arise in glutaric aciduria patients?
The overall vision of the research program is to develop chemical probes and obtain high-resolution
crystal structures to better understand key enzymes in these metabolic pathways and determine if they are
therapeutic targets for human diseases. Within the context of the Mount Sinai research community, we are
well-positioned to collaborate with our colleagues to leverage our strength in chemical and structural biology to
provide molecular understanding that synergizes with our colleagues’ expertise in human biology or medicinal
chemistry, like our overarching collaboration with the Drug Discovery Institute here and our collaborations that
involve cancer, genetic diseases, diabetes, and neurodegeneration. As new opportunities arise, we can
provide our expertise in the molecular underpinnings of glycosyltransferases, kinases and pseudokinases, and
protein degradation pathways to develop new projects supported by the MIRA funding, while still focusing on
the core projects described above.
项目总结
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Michael Block Lazarus其他文献
Michael Block Lazarus的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Michael Block Lazarus', 18)}}的其他基金
Exploring autophagy as a target for Alzheimer's Disease
探索自噬作为阿尔茨海默病的靶标
- 批准号:
10194214 - 财政年份:2021
- 资助金额:
$ 46.45万 - 项目类别:
Exploring autophagy as a target for Alzheimer's Disease
探索自噬作为阿尔茨海默病的靶标
- 批准号:
10380139 - 财政年份:2021
- 资助金额:
$ 46.45万 - 项目类别:
Chemical and structural tools to study energy homeostasis pathways in cancer and diabetes
研究癌症和糖尿病能量稳态途径的化学和结构工具
- 批准号:
9381909 - 财政年份:2017
- 资助金额:
$ 46.45万 - 项目类别:
Chemical and structural tools to study energy homeostasis pathways in cancer and diabetes
研究癌症和糖尿病能量稳态途径的化学和结构工具
- 批准号:
9752600 - 财政年份:2017
- 资助金额:
$ 46.45万 - 项目类别:
Chemical and Structural Approaches to Study Energy Homeostasis Pathways in Cancer and Metabolic disorders
研究癌症和代谢紊乱能量稳态途径的化学和结构方法
- 批准号:
10769149 - 财政年份:2017
- 资助金额:
$ 46.45万 - 项目类别:
Chemical and structural tools to study energy homeostasis pathways in cancer and diabetes
研究癌症和糖尿病能量稳态途径的化学和结构工具
- 批准号:
10226148 - 财政年份:2017
- 资助金额:
$ 46.45万 - 项目类别:
Chemical and Structural Approaches to Study Energy Homeostasis Pathways in Cancer and Metabolic disorders
研究癌症和代谢紊乱能量稳态途径的化学和结构方法
- 批准号:
10662232 - 财政年份:2017
- 资助金额:
$ 46.45万 - 项目类别:
Chemical and Structural Approaches to Study Energy Homeostasis Pathways in Cancer and Metabolic Disorders
研究癌症和代谢紊乱能量稳态途径的化学和结构方法
- 批准号:
10682910 - 财政年份:2017
- 资助金额:
$ 46.45万 - 项目类别:
相似国自然基金
新型F-18标记香豆素衍生物PET探针的研制及靶向Alzheimer's Disease 斑块显像研究
- 批准号:81000622
- 批准年份:2010
- 资助金额:20.0 万元
- 项目类别:青年科学基金项目
阿尔茨海默病(Alzheimer's disease,AD)动物模型构建的分子机理研究
- 批准号:31060293
- 批准年份:2010
- 资助金额:26.0 万元
- 项目类别:地区科学基金项目
跨膜转运蛋白21(TMP21)对引起阿尔茨海默病(Alzheimer'S Disease)的γ分泌酶的作用研究
- 批准号:30960334
- 批准年份:2009
- 资助金额:22.0 万元
- 项目类别:地区科学基金项目
相似海外基金
Pathophysiological mechanisms of hypoperfusion in mouse models of Alzheimer?s disease and small vessel disease
阿尔茨海默病和小血管疾病小鼠模型低灌注的病理生理机制
- 批准号:
10657993 - 财政年份:2023
- 资助金额:
$ 46.45万 - 项目类别:
Social Connectedness and Communication in Parents with Huntington''s Disease and their Offspring: Associations with Psychological and Disease Progression
患有亨廷顿病的父母及其后代的社会联系和沟通:与心理和疾病进展的关联
- 批准号:
10381163 - 财政年份:2022
- 资助金额:
$ 46.45万 - 项目类别:
The Role of Menopause-Driven DNA Damage and Epigenetic Dysregulation in Alzheimer s Disease
更年期驱动的 DNA 损伤和表观遗传失调在阿尔茨海默病中的作用
- 批准号:
10531959 - 财政年份:2022
- 资助金额:
$ 46.45万 - 项目类别:
The Role of Menopause-Driven DNA Damage and Epigenetic Dysregulation in Alzheimer s Disease
更年期驱动的 DNA 损伤和表观遗传失调在阿尔茨海默病中的作用
- 批准号:
10700991 - 财政年份:2022
- 资助金额:
$ 46.45万 - 项目类别:
Interneurons as early drivers of Huntington´s disease progression
中间神经元是亨廷顿病进展的早期驱动因素
- 批准号:
10518582 - 财政年份:2022
- 资助金额:
$ 46.45万 - 项目类别:
Interneurons as Early Drivers of Huntington´s Disease Progression
中间神经元是亨廷顿病进展的早期驱动因素
- 批准号:
10672973 - 财政年份:2022
- 资助金额:
$ 46.45万 - 项目类别:
Social Connectedness and Communication in Parents with Huntington''s Disease and their Offspring: Associations with Psychological and Disease Progression
患有亨廷顿病的父母及其后代的社会联系和沟通:与心理和疾病进展的关联
- 批准号:
10585925 - 财政年份:2022
- 资助金额:
$ 46.45万 - 项目类别:
Oligodendrocyte heterogeneity in Alzheimer' s disease
阿尔茨海默病中的少突胶质细胞异质性
- 批准号:
10180000 - 财政年份:2021
- 资助金额:
$ 46.45万 - 项目类别:
Serum proteome analysis of Alzheimer´s disease in a population-based longitudinal cohort study - the AGES Reykjavik study
基于人群的纵向队列研究中阿尔茨海默病的血清蛋白质组分析 - AGES 雷克雅未克研究
- 批准号:
10049426 - 财政年份:2021
- 资助金额:
$ 46.45万 - 项目类别:
Repurposing drugs for Alzheimer´s disease using a reverse translational approach
使用逆翻译方法重新利用治疗阿尔茨海默病的药物
- 批准号:
10295809 - 财政年份:2021
- 资助金额:
$ 46.45万 - 项目类别:














{{item.name}}会员




